Feasibility and attractiveness of indication value-based pricing in key EU countries
{{output}}
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented wit... ...
